Lung Neoplasms Clinical Trial
— POISEOfficial title:
Pioneering Pre- and Post-Operative Integrative Care to Improve Thoracic Cancer Quality of Care: The Thoracic Peri-Operative Integrative Surgical Care Evaluation (POISE) Trial- Stage I
Verified date | March 2024 |
Source | The Canadian College of Naturopathic Medicine |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Stage I of the Thoracic-POISE study will pilot-test a broad-based, multi-agent integrative care intervention delivered by naturopathic doctors in conjunction with standard surgical and oncologic care of people with thoracic cancer.
Status | Completed |
Enrollment | 22 |
Est. completion date | December 7, 2020 |
Est. primary completion date | December 1, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Adults eligible and scheduled for major thoracic surgery for lung, gastric or esophageal cancer - Candidate for complete resection - Willingness to include an integrative component to their care - Availability for follow-up visits over the course of one year - Willingness to be interviewed regarding their experience of care - Ability to answer self- and interviewer- administered questions in English or French - Understand and sign a written informed consent form in English or French Exclusion Criteria: - Small cell, carcinoid, or gastrointestinal stromal (GIST) tumours - History of cancer in the last 3 years - Already seeing a ND or involved in an integrative program of care in the last 3 months that includes complementary medicine |
Country | Name | City | State |
---|---|---|---|
Canada | Ottawa General Hospital | Ottawa | Ontario |
Canada | Ottawa Integrative Cancer Centre | Ottawa | Ontario |
Lead Sponsor | Collaborator |
---|---|
The Canadian College of Naturopathic Medicine | Lotte & John Hecht Memorial Foundation, Ottawa Hospital Research Institute |
Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Adverse events | Collection of adverse events related to surgery, adjuvant therapy, and the interventions | Enrollment - 1 year post surgery | |
Other | Health Related Quality of Life | Functional Assessment of Cancer Therapy-General Score | Enrollment - 1 year post surgery | |
Other | Cancer-related symptoms | Edmonton Symptom Assessment Scale | Enrollment - 1 year post surgery | |
Other | Anxiety and Depression | Hospital Anxiety and Depression Scale | Enrollment - 1 year post surgery | |
Other | Fatigue | Multidimensional Fatigue Inventory | Enrollment - 1 year post surgery | |
Other | Functional exercise capacity | 6 minute walk test | Enrollment - 1 year post surgery | |
Other | Inflammation: Multi-analyte cytokine array. | Plasma concentrations of a panel of cytokines (IL2, IL10, TGF-beta, TNF-alpha, IFN-alpha, and IFN-gamma) will be measured in blood samples collected 4 weeks before surgery, 2-3 days before surgery, on post-operative day (POD) 1, POD 5 (+/-2), 3-4 weeks, 6 months and 1 year post-surgery | Enrollment - 1 year post surgery | |
Other | Natural kill cell activation | NK cell activity will be measured by NKVue™ in blood samples collected 4 weeks before surgery, 2-3 days before surgery, on post-operative day (POD) 1, POD 5 (+/-2), 3-4 weeks, 6 months and 1 year post-surgery | Enrollment - 1 year post surgery | |
Primary | Feasibility of study protocol | Percentage of participants who complete all assessments and integrative care appointments | Enrollment - 1 year post surgery | |
Secondary | Compliance: supplemental intervention | Count of missed doses assessed by patient diary. | Enrollment - 1 year post surgery | |
Secondary | Compliance: nutritional intervention | Mediterranean diet score calculated by food frequency questionnaire administered at enrollment and 1 year post surgery | Enrollment - 1 year post surgery | |
Secondary | Compliance: physical intervention | Extent of adherence to physical activity recommendations assessed using a patient diary. | Enrollment - 1 year post surgery | |
Secondary | Compliance: mental/emotional domain | Number of days audio-recordings were used assessed by patient diary. | Enrollment - 1 year post surgery | |
Secondary | Communication between practitioners | Number of communications (phone, consult note, etc.) between integrative and standard care practitioners per participant | Enrollment - 1 year post surgery | |
Secondary | Qualitative experience of care and study protocol | Semi-structured interviews with thematic analysis | Enrollment - 1 year post surgery | |
Secondary | Feasibility of recruitment | Percentage of participants recruited out of potentially eligible patients invited. | Enrollment |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03357094 -
Pulmonary Ventilation/Perfusion Imaging for the Prediction of Postoperative Residual Pulmonary Function
|
N/A | |
Recruiting |
NCT05543954 -
68Ga-FAPI-RGD PET/CT Imaging in the Lung Cancer Patients
|
Early Phase 1 | |
Completed |
NCT01114958 -
Pilot Study of Intra-Arterial Cisplatin With IV Thiosulfate in Patients With Lung Cancer or Lung Metastases
|
Phase 1 | |
Recruiting |
NCT06004440 -
Real World Registry for Use of the Ion Endoluminal System
|
||
Completed |
NCT02926768 -
Phase I/II Study of CK-101 in NSCLC Patients and Other Advanced Solid Tumors
|
Phase 1 | |
Not yet recruiting |
NCT02907606 -
Urinary Circulating Tumor DNA Detection in Non-small Cell Lung Cancer: a Prospective Study
|
N/A | |
Active, not recruiting |
NCT02514512 -
Lung Cancer Radiotherapy Using Realtime Dynamic Multileaf Collimator (MLC) Adaptation And Radiofrequency Tracking
|
N/A | |
Completed |
NCT02531737 -
Nintedanib (Vargatef®) Plus Docetaxel in Second Line of Treatment in Patients With Lung Cancer
|
Phase 2 | |
Completed |
NCT02334007 -
Extended Low-Molecular Weight Heparin VTE Prophylaxis in Thoracic Surgery
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT02284633 -
Blood Sample Monitoring of Patients With EGFR Mutated Lung Cancer
|
||
Completed |
NCT02106143 -
RejuvenAir™ System Lobectomy Safety and Histology Study
|
N/A | |
Completed |
NCT01933789 -
Improving Communication About Serious Illness
|
N/A | |
Enrolling by invitation |
NCT01687647 -
Sputum Cytometry Analysis in Lung Cancer Screening After Professional Asbestos Exposure
|
Phase 3 | |
Completed |
NCT00243685 -
Chemotherapy Drug Sensitivity Microculture (MiCK) Assay for Apoptosis
|
Phase 2/Phase 3 | |
Terminated |
NCT00356525 -
Chemotherapy Treatment in Re-occurring Non Small Cell Lung Cancer (NSCLC) After Previous Chemotherapy and Surgical Removal of the NSCLC Tumor
|
Phase 2 | |
Completed |
NCT00351962 -
Phase I/II Study of Fractionated Stereotactic Radiotherapy for Medically Inoperable NSCLC or Metastatic Lung Tumours
|
N/A | |
Completed |
NCT00385177 -
Phase 1 Dose Escalation Study of SN2310 Injectable Emulsion in Patients With Advanced Solid Tumors
|
Phase 1 | |
Completed |
NCT00129844 -
Study of Motexafin Gadolinium (MGd) for Second Line Treatment of Non-Small-Cell Lung Cancer
|
Phase 2 | |
Withdrawn |
NCT00090701 -
A Phase 2, Open-Label, Multicenter Study of the GARFT Inhibitor in Patients With Metastatic Non-Small Cell Lung Cancer
|
Phase 2 | |
Recruiting |
NCT01789229 -
Establishment of a Tumor Bank for Tissue Samples
|